The cAMP-specific phosphodiesterase 4B mediates Aβ-induced microglial activation

Neurobiology of Aging

Volumn 27, Issue 5, 2006, Pages 691-701

  Sebastiani, Giovanna ^a,b   Morissette, Céline ^a,b   Lagacé, Caroline ^a,b   Boulé, Marie ^a,b   Ouellette, Marie Josée ^a,b   McLaughlin, Richard W ^a,b   Lacombe, Diane ^a,b   Gervais, Francine ^b   Tremblay, Patrick ^a,b  

^a Neurochem Inc   (Canada)

^b Parc Scientifique sur le Site de l'EPFL à Ecublens   (Switzerland)

Author keywords

A ; Alzheimer's disease; Array analysis; Pde4B; Primary rat microglial activation

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; COMPLEMENTARY DNA; CYCLIC AMP; INTERLEUKIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; PHOSPHODIESTERASE IV; TUMOR NECROSIS FACTOR ALPHA;

ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; CELL ACTIVATION; CELL STIMULATION; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE COURSE; DNA MICROARRAY; GENE EXPRESSION; GENE IDENTIFICATION; MICROGLIA; NEWBORN; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; RAT; STIMULATION; UPREGULATION;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; AMYLOID BETA-PROTEIN; ANIMALS; CELL SEPARATION; CYTOKINES; DNA, COMPLEMENTARY; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION; ISOENZYMES; MICROGLIA; MICROSCOPY, ELECTRON, TRANSMISSION; NUCLEIC ACID HYBRIDIZATION; PEPTIDE FRAGMENTS; PHOSPHODIESTERASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; ROLIPRAM;

EID: 33646493062     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2005.03.024     Document Type: Article

References (55)

1. Akiyama H., Barger S., Barnum S., et al. Inflammation and Alzheimer's disease. Neurobiol Aging 21 (2000) 383-421
2. Angel J.B., Saget B.M., Walsh S.P., et al. Rolipram, a specific type IV phosphodiesterase inhibitor, is a potent inhibitor of HIV-1 replication. AIDS 9 (1995) 1137-1144
3. Bard F., Cannon C., Barbour R., et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6 (2000) 916-919
4. int' Veld B.A., Ruitenberg A., Hofman A., et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 345 (2001) 1515-1521
5. Bianca V.D., Dusi S., Bianchini E., et al. Beta-amyloid activates the O-2 forming NADPH oxidase in microglia, monocytes, and neutrophils. A possible inflammatory mechanism of neuronal damage in Alzheimer's disease. J Biol Chem 274 (1999) 15493-15499
6. Bolger G., Michaeli T., Martins T., et al. A family of human phosphodiesterases homologous to the dunce learning and memory gene product of Drosophila melanogaster are potential targets for antidepressant drugs. Mol Cell Biol 13 (1993) 6558-6571
7. Bourne H.R., Lichtenstein L.M., Melmon K.L., et al. Modulation of inflammation and immunity by cyclic AMP. Science 184 (1974) 19-28
8. Buttini M., Mir A., Appel K., et al. Lipopolysaccharide induces expression of tumour necrosis factor alpha in rat brain: inhibition by methylprednisolone and by Rolipram. Br J Pharmacol 122 (1997) 1483-1489
9. Casal C., Serratosa J., and Tusell J.M. Relationship between beta-APP peptide aggregation and microglial activation. Brain Res 928 (2002) 76-84
10. Chishti M.A., Yang D.S., Janus C., et al. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J Biol Chem 276 (2001) 21562-21570
11. Combs C.K., Johnson D.E., Cannady S.B., et al. Identification of microglial signal transduction pathways mediating a neurotoxic response to amyloidogenic fragments of beta-amyloid and prion proteins. J Neurosci 19 (1999) 928-939
12. Dahlgren K.N., Manelli A.M., Stine Jr. W.B., et al. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem 277 (2002) 32046-32053
13. DiCarlo G., Wilcock D., Henderson D., et al. Intrahippocampal LPS injections reduce Abeta load in APP+PS1 transgenic mice. Neurobiol Aging 22 (2001) 1007-1012
14. Games D., Adams D., Alessandrini R., et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 373 (1995) 523-527
15. Goodwin J.L., Uemura E., and Cunnick J.E. Microglial release of nitric oxide by the synergistic action of beta-amyloid and IFN-gamma. Brain Res 692 (1995) 207-214
16. Hardy J., and Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 (2002) 353-356
17. Hsiao K.K., Borchelt D.R., Olson K., et al. Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins. Neuron 15 (1995) 1203-1218
18. Itagaki S., McGeer P.L., Akiyama H., et al. Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. J Neuroimmunol 24 (1989) 173-182
19. Jantzen P.T., Connor K.E., DiCarlo G., et al. Microglial activation and beta-amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J Neurosci 22 (2002) 2246-2254
20. Janus C., Pearson J., McLaurin J., et al. Abeta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408 (2000) 979-982
21. Jin S.L., and Conti M. Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses. Proc Natl Acad Sci USA 99 (2002) 7628-7633
22. Kammer G.M. The adenylate cyclase-cAMP-protein kinase A pathway and regulation of the immune response. Immunol Today 9 (1988) 222-229
23. Lambert M.P., Barlow A.K., Chromy B.A., et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 95 (1998) 6448-6453
24. Lim G.P., Yang F., Chu T., et al. Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice. Neurobiol Aging 22 (2001) 983-991
25. Lue L.F., Rydel R., Brigham E.F., et al. Inflammatory repertoire of Alzheimer's disease and nondemented elderly microglia in vitro. GLIA 35 (2001) 72-79
26. McDonald D.R., Brunden K.R., and Landreth G.E. Amyloid fibrils activate tyrosine kinase-dependent signaling and superoxide production in microglia. J Neurosci 17 (1997) 2284-2294
27. McGeer P.L., Itagaki S., Tago H., and McGeer E.G. Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. Neurosci Lett 79 (1987) 195-200
28. McGeer P.L., McGeer E.G., and Inflammation. autotoxicity and Alzheimer disease. Neurobiol Aging 22 (2001) 799-809
29. McGeer P.L., and McGeer E.G. Anti-inflammatory drugs in the fight against Alzheimer's disease. Ann NY Acad Sci 777 (1996) 213-220
30. McGeer P.L., Schulzer M., and McGeer E.G. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 47 (1996) 425-432
31. Meda L., Baron P., Prat E., et al. Proinflammatory profile of cytokine production by human monocytes and murine microglia stimulated with beta-amyloid [25-35]. J Neuroimmunol 93 (1999) 45-52
32. Meda L., Cassatella M.A., Szendrei G.I., et al. Activation of microglial cells by beta-amyloid protein and interferon-gamma. Nature 374 (1995) 647-650
33. Morgan D., Diamond D.M., Gottschall P.E., et al. Abeta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408 (2000) 982-985
34. Morissette C., Boulé M., and Gervais F. Inhibition of β-amyloid peptide-induced microglial cell activation by Congo red and glycosaminoglycans. Neurobiol Aging 23 (2002) S229
35. Nagakura A., Niimura M., and Takeo S. Effects of a phosphodiesterase IV inhibitor Rolipram on microsphere embolism-induced defects in memory function and cerebral cyclic AMP signal transduction system in rats. Br J Pharmacol 135 (2002) 1783-1793
36. Nguyen M.D., Julien J.P., and Rivest S. Innate immunity: the missing link in neuroprotection and neurodegeneration?. Nat Rev Neurosci 3 (2002) 216-227
37. Oddo S., Billings L., Kesslak J.P., et al. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 43 (2004) 321-332
38. Oddo S., Caccamo A., Kitazawa M., et al. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol Aging 24 (2003) 1063-1070
39. Oddo S., Caccamo A., Shepherd J.D., et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles. Intracellular Abeta and synaptic dysfunction. Neuron 39 (2003) 409-421
40. Rozemuller J.M., Eikelenboom P., Pals S.T., and Stam F.C. Microglial cells around amyloid plaques in Alzheimer's disease express leucocyte adhesion molecules of the LFA-1 family. Neurosci Lett 101 (1989) 288-292
41. Sasaki A., Yamaguchi H., Ogawa A., et al. Microglial activation in early stages of amyloid beta protein deposition. Acta Neuropathol (Berl) 94 (1997) 316-322
42. Schenk D., Barbour R., Dunn W., et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400 (1999) 173-177
43. Shalit F., Sredni B., Rosenblatt-Bin H., et al. Beta-amyloid peptide induces tumor necrosis factor-alpha and nitric oxide production in murine macrophage cultures. Neuroreport 8 (1997) 3577-3580
44. Sturchler-Pierrat C., Abramowski D., Duke M., et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci USA 94 (1997) 13287-13292
45. Suyang H., Phillips R., Douglas I., and Ghosh S. Role of unphosphorylated, newly synthesized I kappa B beta in persistent activation of NF-kappa B. Mol Cell Biol 16 (1996) 5444-5449
46. Verghese M.W., McConnell R.T., Strickland A.B., et al. Differential regulation of human monocyte-derived TNF alpha and IL-1 beta by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors. J Pharmacol Exp Ther 272 (1995) 1313-1320
47. Walker D.G., Kim S.U., and McGeer P.L. Complement and cytokine gene expression in cultured microglial derived from postmortem human brains. J Neurosci Res 40 (1995) 478-493
48. Weggen S., Eriksen J.L., Das P., et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414 (2001) 212-216
49. Widmer U., Manogue K.R., Cerami A., and Sherry B. Genomic cloning and promoter analysis of macrophage inflammatory protein (MIP)-2, MIP-1 alpha, and MIP-1 beta, members of the chemokine superfamily of proinflammatory cytokines. J Immunol 150 (1993) 4996-5012
50. Wyss-Coray T., and Mucke L. Inflammation in neurodegenerative disease-a double-edged sword. Neuron 35 (2002) 419-432
51. Yankner B.A., Duffy L.K., and Kirschner D.A. Neurotropic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science 250 (1990) 279-282
52. Yates S.L., Burgess L.H., Kocsis-Angle J., et al. Amyloid beta and amylin fibrils induce increases in proinflammatory cytokine and chemokine production by THP-1 cells and murine microglia. J Neurochem 74 (2000) 1017-1025
53. Zhang B., Yang L., Konishi Y., et al. Suppressive effects of phosphodiesterase type IV inhibitors on rat cultured microglial cells: comparison with other types of cAMP-elevating agents. Neuropharmacology 42 (2002) 262-269
54. Zhang B.H., Tang E.D., Zhu T., et al. Serum- and glucocorticoid-inducible kinase SGK phosphorylates and negatively regulates B-Raf. J Biol Chem 276 (2001) 31620-31626
55. Zuckerman S.H., Gustin J., and Evans G.F. Expression of CD54 (intercellular adhesion molecule-1) and the beta 1 integrin CD29 is modulated by a cyclic AMP dependent pathway in activated primary rat microglial cell cultures. Inflammation 22 (1998) 95-106